We report the case of a 60-year-old man with mild Christmas disease, Factor IX 10 % of normal, who developed chronic hepatitis C infection after receiving coagulation factor concentrates.
The patient originally presented in 1971 (aged 35 years) with an episode of prolonged bleeding from the site of a dental extraction. Investigations led to the diagnosis of mild Christmas disease (Haemophilia B). Over subsequent years he was given fresh frozen plasma and then intravenous coagulation factor concentrates. In 1978, as part of pre-operative management prior to haemorrhoidectomy he was given coagulation factor concentrates, and two weeks following this he developed clinical jaundice with the maximum bilirubin concentration rising to 100 mg/l. It is assumed that the coagulation factor concentrates were infected with hepatitis C virus. Liver function tests were normal pre-operatively. The jaundice rapidly resolved although his liver function tests remained abnormal. He years' and liver transplantation may be required.
Successful liver transplantation in humans with haemophilia was initially described in one patient with severe haemophilia A (Factor VIII deficiency) in 1985.2 The procedure is safe providing that adequate intra-and immediate postoperative coagulation factor replacement is given to avoid bleeding complications and there does not appear to be an excessive transfusion requirement.3 There are reports of three patients with Haemophilia B (4-6), 10 patients with Haemophilia A (3, 4, 7-9 ) and one patient with combined factors VIII and IX deficiency10 who have received liver transplants in the literature. Data on the survival and length of cure of such patients is limited. One report documents survival of 12 months post-transplantation and sustained factor concentrations.4 There is one report of a patient who died intra-operatively which was related to technical difficulties of graft insertion9 and one late mortality due to the development of acquired immunodeficiency syndrome,8 another complication of multitransfused haemophiliacs. Liver transplantation has been used in the treatment of genetic diseases in patients with no significant liver disease.11 A case can be made for liver transplantation prior to the development of liver failure in haemophiliac patients with hepatitis C infection in view of the additional benefits of a phenotypic cure of the clotting abnormality.3 However, this must be viewed in the light of the present shortage of organ donors and the impact on other patients with end-stage liver disease. The mechanism of cure of the coagulation deficiency relates to the fact that the liver is the source of synthesis of the vitamin K dependent coagulation factors (including Factor IX) and since the graft originated from a nonhaemophiliac patient there is a phenotypic cure of the coagulation deficiency. The main long-term problem with liver transplantation for hepatitis C induced cirrhosis is allograft reinfection with HCV, which usually runs a benign course12 although it may progress to cirrhosis within 1-2 years.'3 The time taken for the restoration of normal coagulation factors may be as short as 12 hours4 and a sustained response at 72 hours confirms de novo synthesis of clotting factors by the graft. Further follow-up is required to determine if there is a sustained cure of the haemophilia and to see the outcome of the continuing HCV infection.
